SQZ Biotechnologies (NYSE:SQZ – Get Free Report) and Entera Bio (NASDAQ:ENTX – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, risk, valuation, institutional ownership, analyst recommendations and earnings.
Analyst Ratings
This is a summary of current recommendations and price targets for SQZ Biotechnologies and Entera Bio, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| SQZ Biotechnologies | 0 | 0 | 0 | 0 | N/A |
| Entera Bio | 0 | 0 | 1 | 0 | 3.00 |
Entera Bio has a consensus target price of $10.00, indicating a potential upside of 383.09%. Given Entera Bio’s higher possible upside, analysts plainly believe Entera Bio is more favorable than SQZ Biotechnologies.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| SQZ Biotechnologies | $18.16 million | 0.71 | -$79.46 million | ($2.61) | -0.17 |
| Entera Bio | $130,000.00 | 569.73 | -$8.89 million | ($0.28) | -7.39 |
Entera Bio has lower revenue, but higher earnings than SQZ Biotechnologies. Entera Bio is trading at a lower price-to-earnings ratio than SQZ Biotechnologies, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares SQZ Biotechnologies and Entera Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| SQZ Biotechnologies | -369.96% | -119.83% | -59.90% |
| Entera Bio | N/A | -103.40% | -85.00% |
Risk and Volatility
SQZ Biotechnologies has a beta of 2.34, meaning that its stock price is 134% more volatile than the S&P 500. Comparatively, Entera Bio has a beta of 1.59, meaning that its stock price is 59% more volatile than the S&P 500.
Institutional & Insider Ownership
38.5% of SQZ Biotechnologies shares are held by institutional investors. Comparatively, 14.1% of Entera Bio shares are held by institutional investors. 16.0% of SQZ Biotechnologies shares are held by company insiders. Comparatively, 8.9% of Entera Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
Entera Bio beats SQZ Biotechnologies on 7 of the 12 factors compared between the two stocks.
About SQZ Biotechnologies
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
About Entera Bio
Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
Receive News & Ratings for SQZ Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SQZ Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.
